IIM
MGX icon

INTECH Investment Management’s Metagenomi Therapeutics MGX Stock Holding History

INTECH Investment Management’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-23,200
Closed -$31.6K – 2698
2025
Q1 		$31.6K Buy
+23,200
New +$55.3K ﹤0.01% 2475

Other funds holding MGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

INTECH Investment Management's MGX Position: Q2 2025 in Review

INTECH Investment Management sold out of Metagenomi Therapeutics (MGX) in Q2 2025, closing a stake of 23,200 shares — an estimated $31.6K sold.

INTECH Investment Management first reported a position in MGX in Q1 2025 and held it in 1 quarter. The position peaked at $31.6K in Q1 2025. 69 funds tracked by Wall St. Rank hold MGX as of Q2 2025.

  • INTECH Investment Management reported no remaining Metagenomi Therapeutics position as of Q2 2025 after selling out during the quarter.
  • INTECH Investment Management sold 23,200 Metagenomi Therapeutics shares in Q2 2025, an estimated $31.6K.
  • INTECH Investment Management first reported a position in Metagenomi Therapeutics in Q1 2025 and held it in 1 quarter.
  • INTECH Investment Management's Metagenomi Therapeutics position peaked at $31.6K in Q1 2025.
  • 69 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2025.

Based on INTECH Investment Management's 13F filing for Q2 2025, filed 8 Aug 2025.